SEATTLE--(BUSINESS WIRE)--Aug. 4, 2016--
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced that the company will issue its second
quarter 2016 financial results for the period ended June 30, 2016, on
Tuesday, August 9, 2016, after the market closes. Omeros management will
host a conference call and webcast that day at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time) to discuss the financial results.
Conference Call Details
To access the live conference call via phone, please dial 844-831-4029
from the United States and Canada or 920-663-6278 internationally. The
participant passcode is 60834344. Please dial in approximately 10
minutes prior to the start of the call. A telephone replay will be
available for one week following the call and may be accessed by dialing
855-859-2056 from the United States and Canada or 404-537-3406
internationally. The replay passcode is 60834344.
To access the live and subsequently archived webcast of the conference
call, go to Omeros’ website at www.omeros.com
and go to “Events” under the Investors section of the website. Please
connect to the website at least 15 minutes prior to the call to allow
for any software download that may be necessary.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering,
developing and commercializing both small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, coagulopathies and disorders of the central nervous
system. Derived from its proprietary PharmacoSurgery® platform, the
company’s first drug product, OMIDRIA® (phenylephrine and ketorolac
injection) 1%/0.3%, was broadly launched in the U.S. in April 2015 for
use during cataract surgery or intraocular lens (IOL) replacement to
maintain pupil size by preventing intraoperative miosis (pupil
constriction) and to reduce postoperative ocular pain. In the European
Union, the European Commission has approved OMIDRIA for use in cataract
surgery and lens replacement procedures to maintain mydriasis (pupil
dilation), prevent miosis (pupil constriction) and to reduce
postoperative eye pain. Omeros has five clinical-stage development
programs focused on: complement-related thrombotic microangiopathies,
complement-mediated glomerulopathies, Huntington’s disease and cognitive
impairment, addictive and compulsive disorders, and preventing problems
associated with urologic surgical procedures. In addition, Omeros has a
proprietary GPCR platform, which is making available an unprecedented
number of new GPCR drug targets and corresponding compounds to the
pharmaceutical industry for drug development, and a platform used to
generate antibodies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160804005479/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Investor and Media Relations
Jennifer
Cook Williams, 360-668-3701
